Data from Almirall, Forest Labs’ aclidinium studies on COPD to be presented at ATS conference

Forest Laboratories, Inc. (NYSE: FRX) and Almirall, S.A. (ALM.MC) today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic Society (ATS) International Conference scheduled May 18 - 23 in San Francisco, CA. Positive top-line results from the aclidinium pivotal double-blind placebo-controlled studies were first reported in 2011. Aclidinium bromide is a new, inhaled long-acting antimuscarinic agent currently under review by the FDA for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).    

The poster discussion titled "Long-Term Efficacy And Safety of Twice-Daily Aclidinium Bromide in COPD Patients: A One-Year Study" will take place on Sunday, May 20 from 2:00 - 4:30 pm. This presentation will report the results from the long-term efficacy and safety study of aclidinium bromide in 600 patients over 52 weeks of treatment.

In addition, there will be the following poster presentations:

• Long-Term Extension Study Of ACCORD COPD I: Effects Of Two Doses Of Twice-Daily Aclidinium Bromide In COPD Patients (Poster D43: Monday, May 21 from 8:15 am - 4:30 pm)
• Nighttime Symptoms Of COPD And Associated Reductions In Quality Of Life In A Clinical Trial Population (Poster D56: Wednesday, May 23 from 8:15 am - 4:30 pm)
• COPD Patients' Experience Of Early Morning Symptoms: Results From Qualitative Research (Poster D57: Wednesday, May 23 from 8:15 am - 4:30 pm)